文献速递传染病防控与疫情报告卫生政策与健康促进

2020至2022年英格兰关键人口学与临床亚组中COVID-19相关死亡率的变化:基于OpenSAFELY平台的回顾性队列研究

Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform.
PubMed 文献 · Lancet Public Health · 2023-01-01

结果显示粗死亡率从第一波4.48例/1000人年降至第二波2.69、第三波0.64、第四波1.01、第五波0.67;绝对死亡率整体下降,但接种覆盖率低或免疫应答受损人群的相对风险持续存在且恶化。

要点

  • 英格兰前五波COVID-19粗死亡率从第一波4.48例/1000人年降至第五波0.67例/1000人年。
  • 第一波标准化死亡率最高为80岁及以上、慢性肾病4-5期、透析、痴呆或学习障碍及肾移植者,达19.85-44.41例/1000人年。
  • 第三波较第一波,80岁及以上及神经疾病、学习障碍或严重精神疾病者死亡率下降90-91%,而移植、慢性肾病、血液恶性肿瘤或免疫抑制者仅下降0-25%。

核心结论

  • 总体人群COVID-19绝对死亡 rates 随时间大幅下降,但接种覆盖率低或免疫应答受损人群的人口学与临床相对风险持续存在且恶化。
  • 研究结果为英国公共卫生政策保护这些脆弱亚组提供了证据基础。

研究设计与样本

  • 在英格兰利用OpenSAFELY平台开展的回顾性队列研究,经英格兰国家医疗服务体系批准。
  • 覆盖前五波SARS-CoV-2大流行:第一波(野生型)2020年3月23日至5月30日;第二波(alpha,B.1.1.7)2020年9月7日至2021年4月24日;第三波(delta,B.1.617.2)2021年5月28日至12月14日;第四波(omicron,B.1.1.529)2021年12月15日至2022年4月29日;第五波(omicron)2022年6月24日至8月3日。
  • 每波纳入18-110岁、在该波首日已注册全科诊所且截至该日连续注册至少3个月者。
  • 第一波纳入18 895 870名成人,第二波19 014 720名,第三波18 932 050名,第四波19 097 970名,第五波19 226 475名。
  • 估算粗率及按性别和年龄标准化的波特异性COVID-19相关死亡率及亚组相对风险。

主要发现

  • 粗COVID-19相关死亡率从第一波4.48例/1000人年(95%CI 4.41-4.55)降至第二波2.69(2.66-2.72)、第三波0.64(0.63-0.66)、第四波1.01(0.99-1.03)、第五波0.67(0.64-0.71)。
  • 第一波标准化COVID-19相关死亡率最高者为80岁及以上、慢性肾病5或4期、接受透析、痴呆或学习障碍及接受肾移植者,范围为19.85至44.41例/1000人年,其他亚组为0.05至15.93例/1000人年。
  • 第二波较第一波,在 largely 未接种疫苗人群中,COVID-19相关死亡率下降在各亚组间均匀分布。
  • 第三波较第一波,优先接种 primary SARS-CoV-2疫苗的人群死亡率下降更大,包括80岁及以上及神经疾病、学习障碍或严重精神疾病者(下降90-91%);较年轻年龄组、接受器官移植者及慢性肾病、血液恶性肿瘤或免疫抑制状况者下降较小(下降0-25%)。
  • 第四波较第一波,接种覆盖率较低人群(包括较年轻年龄组)及与疫苗应答受损相关的状况(包括接受器官移植者和免疫抑制状况者)死亡率下降较小(下降26-61%)。

临床怎么用

  • 作者认为,研究结果为英国公共卫生政策保护接种覆盖率低或免疫应答受损的脆弱亚组提供了证据基础。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: COVID-19 has been shown to differently affect various demographic and clinical population subgroups. We aimed to describe trends in absolute and relative COVID-19-related mortality risks across clinical and demographic population subgroups during successive SARS-CoV-2 pandemic waves. METHODS: We did a retrospective cohort study in England using the OpenSAFELY platform with the approval of National Health Service England, covering the first five SARS-CoV-2 pandemic waves (wave one [wild-type] from March 23 to May 30, 2020; wave two [alpha (B.1.1.7)] from Sept 7, 2020, to April 24, 2021; wave three [delta (B.1.617.2)] from May 28 to Dec 14, 2021; wave four [omicron (B.1.1.529)] from Dec 15, 2021, to April 29, 2022; and wave five [omicron] from June 24 to Aug 3, 2022). In each wave, we included people aged 18-110 years who were registered with a general practice on the first day of the wave and who had at least 3 months of continuous general practice registration up to this date. We estimated crude and sex-standardised and age-standardised wave-specific COVID-19-related death rates and relative risks of COVID-19-related death in population subgroups. FINDINGS: 18 895 870 adults were included in wave one, 19 014 720 in wave two, 18 932 050 in wave three, 19 097 970 in wave four, and 19 226 475 in wave five. Crude COVID-19-related death rates per 1000 person-years decreased from 4·48 deaths (95% CI 4·41-4·55) in wave one to 2·69 (2·66-2·72) in wave two, 0·64 (0·63-0·66) in wave three, 1·01 (0·99-1·03) in wave four, and 0·67 (0·64-0·71) in wave five. In wave one, the standardised COVID-19-related death rates were highest in people aged 80 years or older, people with chronic kidney disease stage 5 or 4, people receiving dialysis, people with dementia or learning disability, and people who had received a kidney transplant (ranging from 19·85 deaths per 1000 person-years to 44·41 deaths per 1000 person-years, compared with from 0·05 deaths per 1000 person-years to 15·93 deaths per 1000 person-years in other subgroups). In wave two compared with wave one, in a largely unvaccinated population, the decrease in COVID-19-related mortality was evenly distributed across population subgroups. In wave three compared with wave one, larger decreases in COVID-19-related death rates were seen in groups prioritised for primary SARS-CoV-2 vaccination, including people aged 80 years or older and people with neurological disease, learning disability, or severe mental illness (90-91% decrease). Conversely, smaller decreases in COVID-19-related death rates were observed in younger age groups, people who had received organ transplants, and people with chronic kidney disease, haematological malignancies, or immunosuppressive conditions (0-25% decrease). In wave four compared with wave one, the decrease in COVID-19-related death rates was smaller in groups with lower vaccination coverage (including younger age groups) and conditions associated with impaired vaccine response, including people who had received organ transplants and people with immunosuppressive conditions (26-61% decrease). INTERPRETATION: There was a substantial decrease in absolute COVID-19-related death rates over time in the overall population, but demographic and clinical relative risk profiles persisted and worsened for people with lower vaccination coverage or impaired immune response. Our findings provide an evidence base to inform UK public health policy for protecting these vulnerable population subgroups. FUNDING: UK Research and Innovation, Wellcome Trust, UK Medical Research Council, National Institute for Health and Care Research, and Health Data Research UK.

来源:Lancet Public Health,查看原文。版权归原作者所有。

引用

  1. Nab L, Parker EPK, Andrews CD, et al. Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform. Lancet Public Health. 2023. PMID: 37120260. doi:10.1016/S2468-2667(23)00079-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。